Clinical Trials Browser

Completed × acalabrutinib × 1 year × Clear all

Chromosome 17 deletion, Leukemia, Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02296918 2025-12-19

Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL

Phase 1 Completed

69 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

NCT02362035 2025-12-11

KEYNOTE145

Phase 1/2 Completed

161 enrolled 29 charts

LymphoidOther hematologic neoplasmPlasma cell

Burkitt Lymphoma, Hodgkin Disease, Leukemia, Hairy Cell, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT04008706 2025-12-01

ASSURE

Phase 3 Completed

552 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04883749 2025-06-08

CLL-Frail

Phase 2 Completed

53 enrolled

LymphoidOther hematologic neoplasm

Leukemia, B-Cell

NCT04402138 2025-05-13

Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma

Phase 2 Completed

15 enrolled 10 charts

Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT03623373 2025-05-04

Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma

Phase 2 Completed

13 enrolled 11 charts

Lymphoid

Lymphoma, Mantle-Cell

Clinical Trials

Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL

Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL

KEYNOTE145

ASSURE

CLL-Frail

Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma

Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma